

# Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

## Anti-HMGCR antibody [CL0260]

RRID:AB\_2928124

Type: Antibody

### Proper Citation

Abcam Cat# ab242315, RRID:AB\_2928124

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2928124](http://antibodyregistry.org/AB_2928124)

**Proper Citation:** Abcam Cat# ab242315, RRID:AB\_2928124

**Target Antigen:** HMGCR

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: WB, IHC-P

**Antibody Name:** Anti-HMGCR antibody [CL0260]

**Description:** This monoclonal targets HMGCR

**Target Organism:** human

**Clone ID:** CL0260

**Antibody ID:** AB\_2928124

**Vendor:** Abcam

**Catalog Number:** ab242315

**Record Creation Time:** 20231110T031254+0000

**Record Last Update:** 20260829T192534+0000

### Ratings and Alerts

No rating or validation information has been found for Anti-HMGCR antibody [CL0260].

No alerts have been found for Anti-HMGCR antibody [CL0260].

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Zhang Y, et al. (2026) Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma. *Clinical and molecular hepatology*, 32(2), 866.

Ada SK, et al. (2026) TMEM97 regulates cholesterol biosynthesis and mitochondrial metabolism in gastric carcinoma. *iScience*, 29(8), 116773.

Ma H, et al. (2026) BCAA metabolism promotes lung cancer tumorigenesis by enhancing cholesterol biosynthesis. *Cell reports*, 45(7), 117641.

Yi SA, et al. (2024) mTORC1-CTLH E3 ligase regulates the degradation of HMG-CoA synthase 1 through the Pro/N-degron pathway. *Molecular cell*, 84(11), 2166.

Zhang Q, et al. (2023) Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET. *Cell reports. Medicine*, 4(2), 100934.

Pan Y, et al. (2023) METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. *Cell reports. Medicine*, 4(8), 101144.